Differential role of angiogenesis and tumour cell proliferation in brain metastases according to primary tumour type: analysis of 639 cases

Aim We aimed to characterize angiogenesis and proliferation and their correlation with clinical characteristics in a large brain metastasis (BM) series. Methods Ki67 proliferation index, microvascular density (MVD) and hypoxia‐inducible factor 1 alpha (HIF‐1 alpha) index were determined by immunohis...

Full description

Saved in:
Bibliographic Details
Published inNeuropathology and applied neurobiology Vol. 41; no. 2; pp. e41 - e55
Main Authors Berghoff, Anna S., Ilhan-Mutlu, Aysegül, Dinhof, Carina, Magerle, Manuel, Hackl, Monika, Widhalm, Georg, Hainfellner, Johannes A., Dieckmann, Karin, Pichler, Josef, Hutterer, Markus, Melchardt, Thomas, Bartsch, Rupert, Zielinski, Christoph C., Birner, Peter, Preusser, Matthias
Format Journal Article
LanguageEnglish
Published England Blackwell Publishing Ltd 01.02.2015
Wiley Subscription Services, Inc
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Aim We aimed to characterize angiogenesis and proliferation and their correlation with clinical characteristics in a large brain metastasis (BM) series. Methods Ki67 proliferation index, microvascular density (MVD) and hypoxia‐inducible factor 1 alpha (HIF‐1 alpha) index were determined by immunohistochemistry in BM and primary tumour specimens. Results Six hundred thirty‐nine BM specimens of 639 patients with lung cancer (344/639; 53.8%), breast cancer (105/639; 16.4%), melanoma (67/639; 10.5%), renal cell carcinoma (RCC; 52/639; 8.1%) or colorectal cancer (CRC; 71/639; 11.1%) were available. Specimens of the corresponding primary tumour were available in 113/639 (17.7%) cases. Median Ki67 index was highest in CRC BM and lowest in RCC BM (P < 0.001). MVD and HIF‐1 alpha index were both highest in RCC BM and lowest in melanoma BM (P < 0.001). Significantly higher Ki67 indices, MVD and HIF‐1 alpha indices in the BM than in matched primary tumours were observed for breast cancer, non‐small cell lung cancer (NSCLC) and CRC. Correlation of tissue‐based parameters with overall survival in individual tumour types showed a favourable and independent prognostic impact of low Ki67 index [hazard ratio (HR) 1.015; P < 0.001] in NSCLC BM and of low Ki67 index (HR 1.027; P = 0.008) and high angiogenic activity (HR 1.877; P = 0.002) in RCC. Conclusion Our data argue for differential pathobiological and clinical relevance of Ki67 index, HIF1‐alpha index and MVD between primary tumour types in BM patients. An independent prognostic impact of tissue‐based characteristics was observed in patients with BM from NSCLC and RCC, supporting the incorporation of these tissue‐based parameters into diagnosis‐specific prognostic scores.
AbstractList Aim We aimed to characterize angiogenesis and proliferation and their correlation with clinical characteristics in a large brain metastasis (BM) series. Methods Ki67 proliferation index, microvascular density (MVD) and hypoxia‐inducible factor 1 alpha (HIF‐1 alpha) index were determined by immunohistochemistry in BM and primary tumour specimens. Results Six hundred thirty‐nine BM specimens of 639 patients with lung cancer (344/639; 53.8%), breast cancer (105/639; 16.4%), melanoma (67/639; 10.5%), renal cell carcinoma (RCC; 52/639; 8.1%) or colorectal cancer (CRC; 71/639; 11.1%) were available. Specimens of the corresponding primary tumour were available in 113/639 (17.7%) cases. Median Ki67 index was highest in CRC BM and lowest in RCC BM (P < 0.001). MVD and HIF‐1 alpha index were both highest in RCC BM and lowest in melanoma BM (P < 0.001). Significantly higher Ki67 indices, MVD and HIF‐1 alpha indices in the BM than in matched primary tumours were observed for breast cancer, non‐small cell lung cancer (NSCLC) and CRC. Correlation of tissue‐based parameters with overall survival in individual tumour types showed a favourable and independent prognostic impact of low Ki67 index [hazard ratio (HR) 1.015; P < 0.001] in NSCLC BM and of low Ki67 index (HR 1.027; P = 0.008) and high angiogenic activity (HR 1.877; P = 0.002) in RCC. Conclusion Our data argue for differential pathobiological and clinical relevance of Ki67 index, HIF1‐alpha index and MVD between primary tumour types in BM patients. An independent prognostic impact of tissue‐based characteristics was observed in patients with BM from NSCLC and RCC, supporting the incorporation of these tissue‐based parameters into diagnosis‐specific prognostic scores.
AIMWe aimed to characterize angiogenesis and proliferation and their correlation with clinical characteristics in a large brain metastasis (BM) series.METHODSKi67 proliferation index, microvascular density (MVD) and hypoxia-inducible factor 1 alpha (HIF-1 alpha) index were determined by immunohistochemistry in BM and primary tumour specimens.RESULTSSix hundred thirty-nine BM specimens of 639 patients with lung cancer (344/639; 53.8%), breast cancer (105/639; 16.4%), melanoma (67/639; 10.5%), renal cell carcinoma (RCC; 52/639; 8.1%) or colorectal cancer (CRC; 71/639; 11.1%) were available. Specimens of the corresponding primary tumour were available in 113/639 (17.7%) cases. Median Ki67 index was highest in CRC BM and lowest in RCC BM (P < 0.001). MVD and HIF-1 alpha index were both highest in RCC BM and lowest in melanoma BM (P < 0.001). Significantly higher Ki67 indices, MVD and HIF-1 alpha indices in the BM than in matched primary tumours were observed for breast cancer, non-small cell lung cancer (NSCLC) and CRC. Correlation of tissue-based parameters with overall survival in individual tumour types showed a favourable and independent prognostic impact of low Ki67 index [hazard ratio (HR) 1.015; P < 0.001] in NSCLC BM and of low Ki67 index (HR 1.027; P = 0.008) and high angiogenic activity (HR 1.877; P = 0.002) in RCC.CONCLUSIONOur data argue for differential pathobiological and clinical relevance of Ki67 index, HIF1-alpha index and MVD between primary tumour types in BM patients. An independent prognostic impact of tissue-based characteristics was observed in patients with BM from NSCLC and RCC, supporting the incorporation of these tissue-based parameters into diagnosis-specific prognostic scores.
Aim We aimed to characterize angiogenesis and proliferation and their correlation with clinical characteristics in a large brain metastasis ( BM ) series. Methods K i67 proliferation index, microvascular density ( MVD ) and hypoxia‐inducible factor 1 alpha ( HIF ‐1 alpha) index were determined by immunohistochemistry in BM and primary tumour specimens. Results Six hundred thirty‐nine BM specimens of 639 patients with lung cancer (344/639; 53.8%), breast cancer (105/639; 16.4%), melanoma (67/639; 10.5%), renal cell carcinoma ( RCC ; 52/639; 8.1%) or colorectal cancer ( CRC ; 71/639; 11.1%) were available. Specimens of the corresponding primary tumour were available in 113/639 (17.7%) cases. Median K i67 index was highest in CRC BM and lowest in RCC BM ( P  < 0.001). MVD and HIF ‐1 alpha index were both highest in RCC BM and lowest in melanoma BM ( P  < 0.001). Significantly higher K i67 indices, MVD and HIF ‐1 alpha indices in the BM than in matched primary tumours were observed for breast cancer, non‐small cell lung cancer ( NSCLC ) and CRC . Correlation of tissue‐based parameters with overall survival in individual tumour types showed a favourable and independent prognostic impact of low K i67 index [hazard ratio ( HR ) 1.015; P  < 0.001] in NSCLC BM and of low K i67 index ( HR 1.027; P  = 0.008) and high angiogenic activity ( HR 1.877; P  = 0.002) in RCC . Conclusion Our data argue for differential pathobiological and clinical relevance of K i67 index, HIF 1‐alpha index and MVD between primary tumour types in BM patients. An independent prognostic impact of tissue‐based characteristics was observed in patients with BM from NSCLC and RCC , supporting the incorporation of these tissue‐based parameters into diagnosis‐specific prognostic scores.
We aimed to characterize angiogenesis and proliferation and their correlation with clinical characteristics in a large brain metastasis (BM) series. Ki67 proliferation index, microvascular density (MVD) and hypoxia-inducible factor 1 alpha (HIF-1 alpha) index were determined by immunohistochemistry in BM and primary tumour specimens. Six hundred thirty-nine BM specimens of 639 patients with lung cancer (344/639; 53.8%), breast cancer (105/639; 16.4%), melanoma (67/639; 10.5%), renal cell carcinoma (RCC; 52/639; 8.1%) or colorectal cancer (CRC; 71/639; 11.1%) were available. Specimens of the corresponding primary tumour were available in 113/639 (17.7%) cases. Median Ki67 index was highest in CRC BM and lowest in RCC BM (P < 0.001). MVD and HIF-1 alpha index were both highest in RCC BM and lowest in melanoma BM (P < 0.001). Significantly higher Ki67 indices, MVD and HIF-1 alpha indices in the BM than in matched primary tumours were observed for breast cancer, non-small cell lung cancer (NSCLC) and CRC. Correlation of tissue-based parameters with overall survival in individual tumour types showed a favourable and independent prognostic impact of low Ki67 index [hazard ratio (HR) 1.015; P < 0.001] in NSCLC BM and of low Ki67 index (HR 1.027; P = 0.008) and high angiogenic activity (HR 1.877; P = 0.002) in RCC. Our data argue for differential pathobiological and clinical relevance of Ki67 index, HIF1-alpha index and MVD between primary tumour types in BM patients. An independent prognostic impact of tissue-based characteristics was observed in patients with BM from NSCLC and RCC, supporting the incorporation of these tissue-based parameters into diagnosis-specific prognostic scores.
Aim We aimed to characterize angiogenesis and proliferation and their correlation with clinical characteristics in a large brain metastasis (BM) series. Methods Ki67 proliferation index, microvascular density (MVD) and hypoxia-inducible factor 1 alpha (HIF-1 alpha) index were determined by immunohistochemistry in BM and primary tumour specimens. Results Six hundred thirty-nine BM specimens of 639 patients with lung cancer (344/639; 53.8%), breast cancer (105/639; 16.4%), melanoma (67/639; 10.5%), renal cell carcinoma (RCC; 52/639; 8.1%) or colorectal cancer (CRC; 71/639; 11.1%) were available. Specimens of the corresponding primary tumour were available in 113/639 (17.7%) cases. Median Ki67 index was highest in CRC BM and lowest in RCC BM (P<0.001). MVD and HIF-1 alpha index were both highest in RCC BM and lowest in melanoma BM (P<0.001). Significantly higher Ki67 indices, MVD and HIF-1 alpha indices in the BM than in matched primary tumours were observed for breast cancer, non-small cell lung cancer (NSCLC) and CRC. Correlation of tissue-based parameters with overall survival in individual tumour types showed a favourable and independent prognostic impact of low Ki67 index [hazard ratio (HR) 1.015; P<0.001] in NSCLC BM and of low Ki67 index (HR 1.027; P=0.008) and high angiogenic activity (HR 1.877; P=0.002) in RCC. Conclusion Our data argue for differential pathobiological and clinical relevance of Ki67 index, HIF1-alpha index and MVD between primary tumour types in BM patients. An independent prognostic impact of tissue-based characteristics was observed in patients with BM from NSCLC and RCC, supporting the incorporation of these tissue-based parameters into diagnosis-specific prognostic scores.
Author Zielinski, Christoph C.
Hainfellner, Johannes A.
Widhalm, Georg
Hackl, Monika
Dinhof, Carina
Berghoff, Anna S.
Dieckmann, Karin
Bartsch, Rupert
Ilhan-Mutlu, Aysegül
Magerle, Manuel
Melchardt, Thomas
Birner, Peter
Pichler, Josef
Preusser, Matthias
Hutterer, Markus
Author_xml – sequence: 1
  givenname: Anna S.
  surname: Berghoff
  fullname: Berghoff, Anna S.
  organization: Institute of Neurology, Medical University of Vienna, Vienna, Austria
– sequence: 2
  givenname: Aysegül
  surname: Ilhan-Mutlu
  fullname: Ilhan-Mutlu, Aysegül
  organization: Comprehensive Cancer Center CNS Tumors Unit, Medical University of Vienna, Vienna, Austria
– sequence: 3
  givenname: Carina
  surname: Dinhof
  fullname: Dinhof, Carina
  organization: Comprehensive Cancer Center CNS Tumors Unit, Medical University of Vienna, Vienna, Austria
– sequence: 4
  givenname: Manuel
  surname: Magerle
  fullname: Magerle, Manuel
  organization: Comprehensive Cancer Center CNS Tumors Unit, Medical University of Vienna, Vienna, Austria
– sequence: 5
  givenname: Monika
  surname: Hackl
  fullname: Hackl, Monika
  organization: Austrian National Cancer Registry, Statistics Austria, ViennaVienna, Austria
– sequence: 6
  givenname: Georg
  surname: Widhalm
  fullname: Widhalm, Georg
  organization: Comprehensive Cancer Center CNS Tumors Unit, Medical University of Vienna, Vienna, Austria
– sequence: 7
  givenname: Johannes A.
  surname: Hainfellner
  fullname: Hainfellner, Johannes A.
  organization: Institute of Neurology, Medical University of Vienna, Vienna, Austria
– sequence: 8
  givenname: Karin
  surname: Dieckmann
  fullname: Dieckmann, Karin
  organization: Comprehensive Cancer Center CNS Tumors Unit, Medical University of Vienna, Vienna, Austria
– sequence: 9
  givenname: Josef
  surname: Pichler
  fullname: Pichler, Josef
  organization: Department of Medicine and Neurooncology, Landes-Nervenklinik Wagner-Jauregg, Linz, Austria
– sequence: 10
  givenname: Markus
  surname: Hutterer
  fullname: Hutterer, Markus
  organization: Department of Neurology, Christian-Doppler-Klinik, Paracelsus Medical University, Salzburg, Austria
– sequence: 11
  givenname: Thomas
  surname: Melchardt
  fullname: Melchardt, Thomas
  organization: 3rd Medical Department, Paracelsus Medical University Hospital Salzburg, Salzburg, Austria
– sequence: 12
  givenname: Rupert
  surname: Bartsch
  fullname: Bartsch, Rupert
  organization: Comprehensive Cancer Center CNS Tumors Unit, Medical University of Vienna, Vienna, Austria
– sequence: 13
  givenname: Christoph C.
  surname: Zielinski
  fullname: Zielinski, Christoph C.
  organization: Comprehensive Cancer Center CNS Tumors Unit, Medical University of Vienna, Vienna, Austria
– sequence: 14
  givenname: Peter
  surname: Birner
  fullname: Birner, Peter
  organization: Comprehensive Cancer Center CNS Tumors Unit, Medical University of Vienna, Vienna, Austria
– sequence: 15
  givenname: Matthias
  surname: Preusser
  fullname: Preusser, Matthias
  email: matthias.preusser@meduniwien.ac.at
  organization: Comprehensive Cancer Center CNS Tumors Unit, Medical University of Vienna, Vienna, Austria
BackLink https://www.ncbi.nlm.nih.gov/pubmed/25256708$$D View this record in MEDLINE/PubMed
BookMark eNp1kd9qFDEYxYO02G31wheQgDd6MW3-TDKJd3Vra6GsRRTFm5CZ-bKkziR1MoPuM_jSzbi7vRAMISHwO-fL4RyjgxADIPSCklOa11mw4ZQyqsQTtKBcioJpTQ7QgnAiCqpKeYSOU7ojhIhK6qfoiAkmZEXUAv258M7BAGH0tsND7ABHh21Y-7iGAMmn_GjxOPVxGnADXYfvM-Wzxo4-BuwDrgebzx5Gm_KGrGiaOLQ-rPEYM-57O2z2FuPmHt5mT9ttZvM8THKNm1n3DB062yV4vrtP0JfL95-XH4qbj1fXy_ObouGaigIUISAlaOCa1K4C20iiWq0db5ksAVQtW2dbRoTg1EnZAFOlq4WtXNXqlp-g11vfnOTnBGk0vU9zNBsgTslQKVjJSq51Rl_9g97lEPnzM1UqVRFCZ-rNlmqGmNIAzuxCG0rM3JDJDZm_DWX25c5xqntoH8l9JRk42wK_fAeb_zuZ1flqb1lsFT6N8PtRYYcfRla8Eubr6srcfrtY0u-378wn_gDBtK2d
CODEN NANEDL
CitedBy_id crossref_primary_10_1186_s13550_023_01052_8
crossref_primary_10_1111_his_12709
crossref_primary_10_1093_annonc_mdw532
crossref_primary_10_1158_1078_0432_CCR_18_1624
crossref_primary_10_1158_0008_5472_CAN_19_3560
crossref_primary_10_1016_j_clineuro_2019_03_016
crossref_primary_10_1093_jnen_nlz007
crossref_primary_10_1007_s11060_016_2235_5
crossref_primary_10_1634_theoncologist_2016_0117
crossref_primary_10_1038_s41588_019_0423_x
crossref_primary_10_1093_neuonc_noac131
crossref_primary_10_1007_s12254_018_0384_2
crossref_primary_10_18632_oncotarget_11488
crossref_primary_10_3390_ijms24043854
crossref_primary_10_1007_s10143_016_0760_5
crossref_primary_10_1007_s10585_016_9832_8
crossref_primary_10_1016_j_clcc_2015_05_009
crossref_primary_10_3390_cancers13040603
crossref_primary_10_1186_s12894_017_0306_3
crossref_primary_10_21294_1814_4861_2020_19_1_119_125
crossref_primary_10_18632_oncotarget_4201
crossref_primary_10_1158_0008_5472_CAN_20_2251
crossref_primary_10_18632_oncotarget_5696
crossref_primary_10_1016_j_critrevonc_2018_08_001
crossref_primary_10_3390_ijms23136934
crossref_primary_10_1016_S0007_4551_18_30381_3
crossref_primary_10_1007_s13277_015_3790_7
crossref_primary_10_1186_s13058_021_01480_1
crossref_primary_10_1002_nbm_4948
crossref_primary_10_1111_1759_7714_12818
crossref_primary_10_1038_s41598_021_90662_0
crossref_primary_10_1093_noajnl_vdaa038
crossref_primary_10_1007_s10585_020_10055_x
crossref_primary_10_1007_s11060_020_03513_9
crossref_primary_10_3389_fonc_2021_670313
crossref_primary_10_1038_s41568_020_00300_6
crossref_primary_10_2217_bmm_2017_0161
crossref_primary_10_1016_j_clineuro_2021_106537
crossref_primary_10_1136_esmoopen_2015_000024
crossref_primary_10_3389_fonc_2021_714514
crossref_primary_10_3390_cancers16122242
Cites_doi 10.1007/s10585-012-9552-7
10.1016/j.cell.2011.02.013
10.1586/era.10.165
10.1016/j.ijrobp.2007.06.074
10.1227/NEU.0000000000000354
10.1007/BF00666038
10.1016/S0895-4356(00)00314-0
10.3109/07357907.2010.535059
10.1007/s11060-013-1194-3
10.1007/s10585-014-9675-0
10.1007/s00066-014-0639-8
10.1111/bju.12263
10.1016/j.clineuro.2013.06.019
10.1016/j.lungcan.2010.08.005
10.1111/j.1750-3639.2003.tb00013.x
10.1016/j.radonc.2011.08.041
10.1016/j.semcancer.2012.06.001
10.1158/1078-0432.CCR-04-1776
10.1158/1078-0432.CCR-09-2439
10.1002/jcb.22214
10.1371/journal.pone.0092311
10.1093/annonc/mdp411
10.1016/j.ejca.2010.11.033
10.3171/2012.2.JNS111353
10.1093/neuonc/not112
10.1016/j.ejca.2012.07.002
10.1007/s11060-009-0061-8
10.1016/j.lungcan.2005.03.036
10.1007/s11060-009-9938-9
10.1038/bjc.2014.71
10.1371/journal.pone.0005857
10.1038/labinvest.2011.153
10.1586/14737140.2013.852067
10.5414/NP300600
10.1111/j.1468-1331.2006.01506.x
10.1038/nm.2072
10.3171/2013.9.JNS13788
10.1111/j.1365-2559.2008.03065.x
ContentType Journal Article
Copyright 2014 British Neuropathological Society
2014 British Neuropathological Society.
Copyright © 2015 British Neuropathological Society
Copyright_xml – notice: 2014 British Neuropathological Society
– notice: 2014 British Neuropathological Society.
– notice: Copyright © 2015 British Neuropathological Society
DBID BSCLL
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7TK
K9.
7X8
DOI 10.1111/nan.12185
DatabaseName Istex
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
Neurosciences Abstracts
ProQuest Health & Medical Complete (Alumni)
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
ProQuest Health & Medical Complete (Alumni)
Neurosciences Abstracts
MEDLINE - Academic
DatabaseTitleList
MEDLINE - Academic
CrossRef
MEDLINE
ProQuest Health & Medical Complete (Alumni)
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1365-2990
EndPage e55
ExternalDocumentID 3572294611
10_1111_nan_12185
25256708
NAN12185
ark_67375_WNG_PXDC1ZPB_R
Genre article
Research Support, Non-U.S. Gov't
Journal Article
GrantInformation_xml – fundername: Medical University of Vienna
  funderid: H‐263727/2013
GroupedDBID ---
.3N
.GA
.GJ
.Y3
05W
0R~
10A
123
1OB
1OC
29N
31~
33P
36B
3SF
3UE
4.4
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
53G
5HH
5LA
5RE
5VS
66C
702
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A01
A03
AAESR
AAEVG
AAHHS
AANLZ
AAONW
AASGY
AAVGM
AAXRX
AAZKR
ABCQN
ABCUV
ABDBF
ABEML
ABHUG
ABJNI
ABPTK
ABPVW
ABQWH
ABXGK
ACAHQ
ACBWZ
ACCFJ
ACCZN
ACGFS
ACGOF
ACMXC
ACPOU
ACPRK
ACSCC
ACXBN
ACXME
ACXQS
ADAWD
ADBBV
ADBTR
ADDAD
ADEOM
ADIZJ
ADKYN
ADMGS
ADOZA
ADXAS
ADZMN
AEEZP
AEIGN
AEIMD
AENEX
AEQDE
AEUQT
AEUYR
AFBPY
AFEBI
AFFNX
AFFPM
AFGKR
AFPWT
AFVGU
AFZJQ
AGJLS
AHBTC
AHEFC
AHMBA
AIACR
AIURR
AIWBW
AJBDE
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
AMBMR
AMYDB
ASPBG
ATUGU
AVWKF
AZBYB
AZFZN
AZVAB
BAFTC
BDRZF
BFHJK
BHBCM
BMXJE
BROTX
BRXPI
BSCLL
BY8
C45
CAG
COF
CS3
D-6
D-7
D-E
D-F
DCZOG
DPXWK
DR2
DRFUL
DRMAN
DRSTM
DU5
EAD
EAP
EAS
EBC
EBD
EBS
EBX
EJD
EMB
EMK
EMOBN
ESX
EX3
F00
F01
F04
F5P
FEDTE
FUBAC
G-S
G.N
GODZA
GSXLS
H.X
HF~
HVGLF
HZI
HZ~
IHE
IX1
J0M
K48
KBYEO
L7B
LATKE
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
MEWTI
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N04
N05
N9A
NF~
O66
O9-
OVD
P2P
P2W
P2X
P2Z
P4B
P4D
PALCI
PQQKQ
Q.N
Q11
QB0
Q~Q
R.K
RIWAO
RJQFR
ROL
RX1
SAMSI
SUPJJ
SV3
TEORI
TUS
UB1
W8V
W99
WBKPD
WH7
WHWMO
WIH
WIJ
WIK
WOHZO
WOW
WQJ
WRC
WUP
WVDHM
WXI
WXSBR
XG1
YFH
ZA5
ZGI
ZXP
ZZTAW
~IA
~WT
AITYG
HGLYW
OIG
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7TK
K9.
7X8
ID FETCH-LOGICAL-c3915-e800e66e9e390bf7eac608d99f3d264ee8b6dfad205531f66ce284fb5a7f7d9d3
IEDL.DBID DR2
ISSN 0305-1846
IngestDate Fri Aug 16 01:33:27 EDT 2024
Fri Sep 13 07:35:29 EDT 2024
Fri Aug 23 00:57:04 EDT 2024
Sat Sep 28 08:12:40 EDT 2024
Sat Aug 24 00:58:49 EDT 2024
Wed Jan 17 05:01:26 EST 2024
IsPeerReviewed true
IsScholarly true
Issue 2
Keywords ki67 proliferation index
microvascular density
HIF-1 alpha index
brain metastases
Language English
License 2014 British Neuropathological Society.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c3915-e800e66e9e390bf7eac608d99f3d264ee8b6dfad205531f66ce284fb5a7f7d9d3
Notes ark:/67375/WNG-PXDC1ZPB-R
ArticleID:NAN12185
Medical University of Vienna - No. H-263727/2013
istex:8B7C749114817DC06F17E09B3B636C3516898B0F
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
PMID 25256708
PQID 1648870019
PQPubID 1096364
PageCount 15
ParticipantIDs proquest_miscellaneous_1652424399
proquest_journals_1648870019
crossref_primary_10_1111_nan_12185
pubmed_primary_25256708
wiley_primary_10_1111_nan_12185_NAN12185
istex_primary_ark_67375_WNG_PXDC1ZPB_R
PublicationCentury 2000
PublicationDate 2015-02
February 2015
2015-Feb
2015-02-00
20150201
PublicationDateYYYYMMDD 2015-02-01
PublicationDate_xml – month: 02
  year: 2015
  text: 2015-02
PublicationDecade 2010
PublicationPlace England
PublicationPlace_xml – name: England
– name: Oxford
PublicationTitle Neuropathology and applied neurobiology
PublicationTitleAlternate Neuropathol Appl Neurobiol
PublicationYear 2015
Publisher Blackwell Publishing Ltd
Wiley Subscription Services, Inc
Publisher_xml – name: Blackwell Publishing Ltd
– name: Wiley Subscription Services, Inc
References Bachtiary B, Schindl M, Potter R, Dreier B, Knocke TH, Hainfellner JA, Horvat R, Birner P. Overexpression of hypoxia-inducible factor 1alpha indicates diminished response to radiotherapy and unfavorable prognosis in patients receiving radical radiotherapy for cervical cancer. Clin Cancer Res 2003; 9: 2234-2240
Preusser M, Heinzl H, Gelpi E, Hoftberger R, Fischer I, Pipp I, Milenkovic I, Wohrer A, Popovici F, Wolfsberger S, Hainfellner JA. Ki67 index in intracranial ependymoma: a promising histopathological candidate biomarker. Histopathology 2008; 53: 39-47
Park S, Ha SY, Cho HY, Chung DH, Kim NR, Hong J, Cho EK. Prognostic implications of hypoxia-inducible factor-1alpha in epidermal growth factor receptor-negative non-small cell lung cancer. Lung Cancer 2011; 72: 100-107
Berghoff AS, Preusser M. Biology in prevention and treatment of brain metastases. Expert Rev Anticancer Ther 2013; 13: 1339-1348
Kienast Y, Winkler F. Therapy and prophylaxis of brain metastases. Expert Rev Anticancer Ther 2010; 10: 1763-1777
Kim SJ, Rabbani ZN, Dewhirst MW, Vujaskovic Z, Vollmer RT, Schreiber EG, Oosterwijk E, Kelley MJ. Expression of HIF-1alpha, CA IX, VEGF, and MMP-9 in surgically resected non-small cell lung cancer. Lung Cancer 2005; 49: 325-335
Shen C, Kaelin WG Jr. The VHL/HIF axis in clear cell renal carcinoma. Semin Cancer Biol 2013; 23: 18-25
Sperduto PW, Berkey B, Gaspar LE, Mehta M, Curran W. A new prognostic index and comparison to three other indices for patients with brain metastases: an analysis of 1,960 patients in the RTOG database. Int J Radiat Oncol Biol Phys 2008; 70: 510-514
Scoccianti S, Ricardi U. Treatment of brain metastases: review of phase III randomized controlled trials. Radiother Oncol 2012; 102: 168-179
Berghoff AS, Ilhan-Mutlu A, Wohrer A, Hackl M, Widhalm G, Hainfellner JA, Dieckmann K, Melchardt T, Dome B, Heinzl H, Birner P, Preusser M. Prognostic significance of Ki67 proliferation index, HIF1 alpha index and microvascular density in patients with non-small cell lung cancer brain metastases. Strahlenther Onkol 2014; 190: 676-685
Gayed BA, Youssef RF, Bagrodia A, Darwish OM, Kapur P, Sagalowsky A, Lotan Y, Margulis V. Ki67 is an independent predictor of oncological outcomes in patients with localized clear-cell renal cell carcinoma. BJU Int 2014; 113: 668-673
Jenkinson MD, Haylock B, Shenoy A, Husband D, Javadpour M. Management of cerebral metastasis: evidence-based approach for surgery, stereotactic radiosurgery and radiotherapy. Eur J Cancer 2011; 47: 649-655
Rades D, Dziggel L, Segedin B, Oblak I, Nagy V, Marita A, Schild SE. The first survival score for patients with brain metastases from small cell lung cancer (SCLC). Clin Neurol Neurosurg 2013; 115: 2029-2032
Harter PN, Zinke J, Scholz A, Tichy J, Zachskorn C, Kvasnicka HM, Goeppert B, Delloye-Bourgeois C, Hattingen E, Senft C, Steinbach JP, Plate KH, Mehlen P, Schulte D, Mittelbronn M. Netrin-1 expression is an independent prognostic factor for poor patient survival in brain metastases. PLoS ONE 2014; 9: e92311
Besse B, Lasserre SF, Compton P, Huang J, Augustus S, Rohr UP. Bevacizumab safety in patients with central nervous system metastases. Clin Cancer Res 2010; 16: 269-278
Carbonell WS, Ansorge O, Sibson N, Muschel R. The vascular basement membrane as 'soil' in brain metastasis. PLoS ONE 2009; 4: e5857
Preusser M, Winkler F, Collette L, Haller S, Marreaud S, Soffietti R, Klein M, Reijneveld JC, Tonn JC, Baumert BG, Mulvenna P, Schadendorf D, Duchnowska R, Berghoff AS, Lin N, Cameron DA, Belkacemi Y, Jassem J, Weber DC. Trial design on prophylaxis and treatment of brain metastases: lessons learned from the EORTC Brain Metastases Strategic Meeting 2012. Eur J Cancer 2012; 48: 3439-3447
Kondziolka D, Kalkanis SN, Mehta MP, Ahluwalia M, Loeffler JS. It is time to reevaluate the management of patients with brain metastases. Neurosurgery 2014; 75: 1-9
Birner P, Piribauer M, Fischer I, Gatterbauer B, Marosi C, Ambros PF, Ambros IM, Bredel M, Oberhuber G, Rossler K, Budka H, Harris AL, Hainfellner JA. Vascular patterns in glioblastoma influence clinical outcome and associate with variable expression of angiogenic proteins: evidence for distinct angiogenic subtypes. Brain Pathol 2003; 13: 133-143
Saroufim A, Messai Y, Hasmim M, Rioux N, Iacovelli R, Verhoest G, Bensalah K, Patard JJ, Albiges L, Azzarone B, Escudier B, Chouaib S. Tumoral CD105 is a novel independent prognostic marker for prognosis in clear-cell renal cell carcinoma. Br J Cancer 2014; 110: 1778-1784
Dudderidge TJ, Stoeber K, Loddo M, Atkinson G, Fanshawe T, Griffiths DF, Williams GH. Mcm2, Geminin, and KI67 define proliferative state and are prognostic markers in renal cell carcinoma. Clin Cancer Res 2005; 11: 2510-2517
Kalkanis SN, Kondziolka D, Gaspar LE, Burri SH, Asher AL, Cobbs CS, Ammirati M, Robinson PD, Andrews DW, Loeffler JS, McDermott M, Mehta MP, Mikkelsen T, Olson JJ, Paleologos NA, Patchell RA, Ryken TC, Linskey ME. The role of surgical resection in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol 2010; 96: 33-43
Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D, Buechler P, Isaacs WB, Semenza GL, Simons JW. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res 1999; 59: 5830-5835
Cochran DC, Chan MD, Aklilu M, Lovato JF, Alphonse NK, Bourland JD, Urbanic JJ, McMullen KP, Shaw EG, Tatter SB, Ellis TL. The effect of targeted agents on outcomes in patients with brain metastases from renal cell carcinoma treated with Gamma Knife surgery. J Neurosurg 2012; 116: 978-983
Wohrer A, Waldhor T, Heinzl H, Hackl M, Feichtinger J, Gruber-Mosenbacher U, Kiefer A, Maier H, Motz R, Reiner-Concin A, Richling B, Idriceanu C, Scarpatetti M, Sedivy R, Bankl HC, Stiglbauer W, Preusser M, Rossler K, Hainfellner JA. The Austrian Brain Tumour Registry: a cooperative way to establish a population-based brain tumour registry. J Neurooncol 2009; 95: 401-411
Berghoff AS, Kovanda AK, Melchardt T, Bartsch R, Hainfellner JA, Sipos B, Schittenhelm J, Zielinski CC, Widhalm G, Dieckmann K, Weller M, Goodman SL, Birner P, Preusser M. Alphavbeta3, alphavbeta5 and alphavbeta6 integrins in brain metastases of lung cancer. Clin Exp Metastasis 2014 (in press)
Wu PF, Huang WC, Yang JC, Lu YS, Shih JY, Wu SG, Lin CH, Cheng AL. Phosphorylated insulin-like growth factor-1 receptor (pIGF1R) is a poor prognostic factor in brain metastases from lung adenocarcinomas. J Neurooncol 2013; 115: 61-70
Soffietti R, Cornu P, Delattre JY, Grant R, Graus F, Grisold W, Heimans J, Hildebrand J, Hoskin P, Kalljo M, Krauseneck P, Marosi C, Siegal T, Vecht C. EFNS Guidelines on diagnosis and treatment of brain metastases: report of an EFNS Task Force. Eur J Neurol 2006; 13: 674-681
Ruan K, Song G, Ouyang G. Role of hypoxia in the hallmarks of human cancer. J Cell Biochem 2009; 107: 1053-1062
Kienast Y, von Baumgarten L, Fuhrmann M, Klinkert WE, Goldbrunner R, Herms J, Winkler F. Real-time imaging reveals the single steps of brain metastasis formation. Nat Med 2010; 16: 116-122
Woehrer A. Brain tumor epidemiology in Austria and the Austrian Brain Tumor Registry. Clin Neuropathol 2013; 32: 269-285
Weidner N. Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors. Breast Cancer Res Treat 1995; 36: 169-180
Massard C, Zonierek J, Gross-Goupil M, Fizazi K, Szczylik C, Escudier B. Incidence of brain metastases in renal cell carcinoma treated with sorafenib. Ann Oncol 2010; 21: 1027-1031
Kondziolka D, Parry PV, Lunsford LD, Kano H, Flickinger JC, Rakfal S, Arai Y, Loeffler JS, Rush S, Knisely JP, Sheehan J, Friedman W, Tarhini AA, Francis L, Lieberman F, Ahluwalia MS, Linskey ME, McDermott M, Sperduto P, Stupp R. The accuracy of predicting survival in individual patients with cancer. J Neurosurg 2014; 120: 24-30
Bleckmann A, Siam L, Klemm F, Rietkotter E, Wegner C, Kramer F, Beissbarth T, Binder C, Stadelmann C, Pukrop T. Nuclear LEF1/TCF4 correlate with poor prognosis but not with nuclear beta-catenin in cerebral metastasis of lung adenocarcinomas. Clin Exp Metastasis 2013; 30: 471-482
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674
Berghoff AS, Rajky O, Winkler F, Bartsch R, Furtner J, Hainfellner JA, Goodman SL, Weller M, Schittenhelm J, Preusser M. Invasion patterns in brain metastases of solid cancers. Neuro-Oncol 2013; 15: 1664-1672
Bender R, Lange S. Adjusting for multiple testing-when and how? J Clin Epidemiol 2001; 54: 343-349
Iakovlev VV, Gabril M, Dubinski W, Scorilas A, Youssef YM, Faragalla H, Kovacs K, Rotondo F, Metias S, Arsanious A, Plotkin A, Girgis AH, Streutker CJ, Yousef GM. Microvascular density as an independent predictor of clinical outcome in renal cell carcinoma: an automated image analysis study. Lab Invest 2012; 92: 46-56
Toma MI, Weber T, Meinhardt M, Zastrow S, Grimm MO, Fussel S, Wirth MP, Baretton GB. Expression of the Forkhead transcription factor FOXP1 is associated with tumor grade and Ki67 expression in clear cell renal cell carcinoma. Cancer Invest 2011; 29: 123-129
2010; 10
2010; 16
2012; 102
2006; 13
1995; 36
2013; 23
2014; 190
2003; 13
2008; 53
2014; 110
2005; 49
2008; 70
2014; 113
2010; 21
2012; 92
2013; 15
2009; 95
2013; 32
2013; 13
2013; 115
1999; 59
2003; 9
2011; 72
2013; 30
2014
2011; 47
2009; 4
2012; 48
2013
2014; 9
2009; 107
2012; 116
2011; 29
2014; 120
2010; 96
2005; 11
2011; 144
2001; 54
2014; 75
e_1_2_8_28_1
e_1_2_8_29_1
e_1_2_8_24_1
e_1_2_8_25_1
e_1_2_8_26_1
Bachtiary B (e_1_2_8_23_1) 2003; 9
e_1_2_8_3_1
e_1_2_8_2_1
e_1_2_8_5_1
e_1_2_8_4_1
e_1_2_8_7_1
e_1_2_8_6_1
e_1_2_8_9_1
e_1_2_8_8_1
e_1_2_8_20_1
e_1_2_8_21_1
e_1_2_8_42_1
e_1_2_8_22_1
e_1_2_8_41_1
e_1_2_8_40_1
e_1_2_8_17_1
e_1_2_8_18_1
e_1_2_8_39_1
e_1_2_8_19_1
e_1_2_8_13_1
e_1_2_8_36_1
e_1_2_8_14_1
e_1_2_8_35_1
e_1_2_8_15_1
e_1_2_8_38_1
e_1_2_8_16_1
e_1_2_8_37_1
Zhong H (e_1_2_8_27_1) 1999; 59
e_1_2_8_32_1
e_1_2_8_10_1
e_1_2_8_31_1
e_1_2_8_11_1
e_1_2_8_34_1
e_1_2_8_12_1
e_1_2_8_33_1
e_1_2_8_30_1
References_xml – volume: 120
  start-page: 24
  year: 2014
  end-page: 30
  article-title: The accuracy of predicting survival in individual patients with cancer
  publication-title: J Neurosurg
– volume: 92
  start-page: 46
  year: 2012
  end-page: 56
  article-title: Microvascular density as an independent predictor of clinical outcome in renal cell carcinoma: an automated image analysis study
  publication-title: Lab Invest
– volume: 13
  start-page: 133
  year: 2003
  end-page: 143
  article-title: Vascular patterns in glioblastoma influence clinical outcome and associate with variable expression of angiogenic proteins: evidence for distinct angiogenic subtypes
  publication-title: Brain Pathol
– volume: 190
  start-page: 676
  year: 2014
  end-page: 685
  article-title: Prognostic significance of Ki67 proliferation index, HIF1 alpha index and microvascular density in patients with non‐small cell lung cancer brain metastases
  publication-title: Strahlenther Onkol
– volume: 53
  start-page: 39
  year: 2008
  end-page: 47
  article-title: Ki67 index in intracranial ependymoma: a promising histopathological candidate biomarker
  publication-title: Histopathology
– volume: 59
  start-page: 5830
  year: 1999
  end-page: 5835
  article-title: Overexpression of hypoxia‐inducible factor 1alpha in common human cancers and their metastases
  publication-title: Cancer Res
– volume: 144
  start-page: 646
  year: 2011
  end-page: 674
  article-title: Hallmarks of cancer: the next generation
  publication-title: Cell
– volume: 29
  start-page: 123
  year: 2011
  end-page: 129
  article-title: Expression of the Forkhead transcription factor FOXP1 is associated with tumor grade and Ki67 expression in clear cell renal cell carcinoma
  publication-title: Cancer Invest
– volume: 36
  start-page: 169
  year: 1995
  end-page: 180
  article-title: Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors
  publication-title: Breast Cancer Res Treat
– volume: 13
  start-page: 674
  year: 2006
  end-page: 681
  article-title: EFNS Guidelines on diagnosis and treatment of brain metastases: report of an EFNS Task Force
  publication-title: Eur J Neurol
– volume: 54
  start-page: 343
  year: 2001
  end-page: 349
  article-title: Adjusting for multiple testing–when and how?
  publication-title: J Clin Epidemiol
– volume: 23
  start-page: 18
  year: 2013
  end-page: 25
  article-title: The VHL/HIF axis in clear cell renal carcinoma
  publication-title: Semin Cancer Biol
– volume: 10
  start-page: 1763
  year: 2010
  end-page: 1777
  article-title: Therapy and prophylaxis of brain metastases
  publication-title: Expert Rev Anticancer Ther
– volume: 47
  start-page: 649
  year: 2011
  end-page: 655
  article-title: Management of cerebral metastasis: evidence‐based approach for surgery, stereotactic radiosurgery and radiotherapy
  publication-title: Eur J Cancer
– volume: 48
  start-page: 3439
  year: 2012
  end-page: 3447
  article-title: Trial design on prophylaxis and treatment of brain metastases: lessons learned from the EORTC Brain Metastases Strategic Meeting 2012
  publication-title: Eur J Cancer
– volume: 75
  start-page: 1
  year: 2014
  end-page: 9
  article-title: It is time to reevaluate the management of patients with brain metastases
  publication-title: Neurosurgery
– volume: 15
  start-page: 1664
  year: 2013
  end-page: 1672
  article-title: Invasion patterns in brain metastases of solid cancers
  publication-title: Neuro‐Oncol
– volume: 107
  start-page: 1053
  year: 2009
  end-page: 1062
  article-title: Role of hypoxia in the hallmarks of human cancer
  publication-title: J Cell Biochem
– volume: 9
  start-page: 2234
  year: 2003
  end-page: 2240
  article-title: Overexpression of hypoxia‐inducible factor 1alpha indicates diminished response to radiotherapy and unfavorable prognosis in patients receiving radical radiotherapy for cervical cancer
  publication-title: Clin Cancer Res
– volume: 21
  start-page: 1027
  year: 2010
  end-page: 1031
  article-title: Incidence of brain metastases in renal cell carcinoma treated with sorafenib
  publication-title: Ann Oncol
– volume: 96
  start-page: 33
  year: 2010
  end-page: 43
  article-title: The role of surgical resection in the management of newly diagnosed brain metastases: a systematic review and evidence‐based clinical practice guideline
  publication-title: J Neurooncol
– volume: 4
  start-page: e5857
  year: 2009
  article-title: The vascular basement membrane as ‘soil’ in brain metastasis
  publication-title: PLoS ONE
– volume: 16
  start-page: 269
  year: 2010
  end-page: 278
  article-title: Bevacizumab safety in patients with central nervous system metastases
  publication-title: Clin Cancer Res
– volume: 9
  start-page: e92311
  year: 2014
  article-title: Netrin‐1 expression is an independent prognostic factor for poor patient survival in brain metastases
  publication-title: PLoS ONE
– volume: 16
  start-page: 116
  year: 2010
  end-page: 122
  article-title: Real‐time imaging reveals the single steps of brain metastasis formation
  publication-title: Nat Med
– year: 2014
  article-title: Alphavbeta3, alphavbeta5 and alphavbeta6 integrins in brain metastases of lung cancer
  publication-title: Clin Exp Metastasis
– volume: 110
  start-page: 1778
  year: 2014
  end-page: 1784
  article-title: Tumoral CD105 is a novel independent prognostic marker for prognosis in clear‐cell renal cell carcinoma
  publication-title: Br J Cancer
– volume: 115
  start-page: 2029
  year: 2013
  end-page: 2032
  article-title: The first survival score for patients with brain metastases from small cell lung cancer (SCLC)
  publication-title: Clin Neurol Neurosurg
– volume: 113
  start-page: 668
  year: 2014
  end-page: 673
  article-title: Ki67 is an independent predictor of oncological outcomes in patients with localized clear‐cell renal cell carcinoma
  publication-title: BJU Int
– volume: 11
  start-page: 2510
  year: 2005
  end-page: 2517
  article-title: Mcm2, Geminin, and KI67 define proliferative state and are prognostic markers in renal cell carcinoma
  publication-title: Clin Cancer Res
– volume: 49
  start-page: 325
  year: 2005
  end-page: 335
  article-title: Expression of HIF‐1alpha, CA IX, VEGF, and MMP‐9 in surgically resected non‐small cell lung cancer
  publication-title: Lung Cancer
– volume: 95
  start-page: 401
  year: 2009
  end-page: 411
  article-title: The Austrian Brain Tumour Registry: a cooperative way to establish a population‐based brain tumour registry
  publication-title: J Neurooncol
– volume: 32
  start-page: 269
  year: 2013
  end-page: 285
  article-title: Brain tumor epidemiology in Austria and the Austrian Brain Tumor Registry
  publication-title: Clin Neuropathol
– volume: 70
  start-page: 510
  year: 2008
  end-page: 514
  article-title: A new prognostic index and comparison to three other indices for patients with brain metastases: an analysis of 1,960 patients in the RTOG database
  publication-title: Int J Radiat Oncol Biol Phys
– volume: 116
  start-page: 978
  year: 2012
  end-page: 983
  article-title: The effect of targeted agents on outcomes in patients with brain metastases from renal cell carcinoma treated with Gamma Knife surgery
  publication-title: J Neurosurg
– volume: 72
  start-page: 100
  year: 2011
  end-page: 107
  article-title: Prognostic implications of hypoxia‐inducible factor‐1alpha in epidermal growth factor receptor‐negative non‐small cell lung cancer
  publication-title: Lung Cancer
– volume: 30
  start-page: 471
  year: 2013
  end-page: 482
  article-title: Nuclear LEF1/TCF4 correlate with poor prognosis but not with nuclear beta‐catenin in cerebral metastasis of lung adenocarcinomas
  publication-title: Clin Exp Metastasis
– volume: 115
  start-page: 61
  year: 2013
  end-page: 70
  article-title: Phosphorylated insulin‐like growth factor‐1 receptor (pIGF1R) is a poor prognostic factor in brain metastases from lung adenocarcinomas
  publication-title: J Neurooncol
– volume: 13
  start-page: 1339
  year: 2013
  end-page: 1348
  article-title: Biology in prevention and treatment of brain metastases
  publication-title: Expert Rev Anticancer Ther
– volume: 102
  start-page: 168
  year: 2012
  end-page: 179
  article-title: Treatment of brain metastases: review of phase III randomized controlled trials
  publication-title: Radiother Oncol
– year: 2013
– ident: e_1_2_8_37_1
  doi: 10.1007/s10585-012-9552-7
– ident: e_1_2_8_7_1
  doi: 10.1016/j.cell.2011.02.013
– ident: e_1_2_8_4_1
  doi: 10.1586/era.10.165
– ident: e_1_2_8_13_1
  doi: 10.1016/j.ijrobp.2007.06.074
– ident: e_1_2_8_21_1
  doi: 10.1227/NEU.0000000000000354
– ident: e_1_2_8_18_1
  doi: 10.1007/BF00666038
– ident: e_1_2_8_19_1
  doi: 10.1016/S0895-4356(00)00314-0
– ident: e_1_2_8_32_1
  doi: 10.3109/07357907.2010.535059
– ident: e_1_2_8_40_1
  doi: 10.1007/s11060-013-1194-3
– ident: e_1_2_8_41_1
  doi: 10.1007/s10585-014-9675-0
– ident: e_1_2_8_15_1
  doi: 10.1007/s00066-014-0639-8
– volume: 9
  start-page: 2234
  year: 2003
  ident: e_1_2_8_23_1
  article-title: Overexpression of hypoxia‐inducible factor 1alpha indicates diminished response to radiotherapy and unfavorable prognosis in patients receiving radical radiotherapy for cervical cancer
  publication-title: Clin Cancer Res
  contributor:
    fullname: Bachtiary B
– ident: e_1_2_8_31_1
  doi: 10.1111/bju.12263
– ident: e_1_2_8_14_1
  doi: 10.1016/j.clineuro.2013.06.019
– ident: e_1_2_8_25_1
  doi: 10.1016/j.lungcan.2010.08.005
– ident: e_1_2_8_16_1
  doi: 10.1111/j.1750-3639.2003.tb00013.x
– ident: e_1_2_8_5_1
  doi: 10.1016/j.radonc.2011.08.041
– ident: e_1_2_8_26_1
  doi: 10.1016/j.semcancer.2012.06.001
– volume: 59
  start-page: 5830
  year: 1999
  ident: e_1_2_8_27_1
  article-title: Overexpression of hypoxia‐inducible factor 1alpha in common human cancers and their metastases
  publication-title: Cancer Res
  contributor:
    fullname: Zhong H
– ident: e_1_2_8_33_1
  doi: 10.1158/1078-0432.CCR-04-1776
– ident: e_1_2_8_28_1
  doi: 10.1158/1078-0432.CCR-09-2439
– ident: e_1_2_8_22_1
  doi: 10.1002/jcb.22214
– ident: e_1_2_8_8_1
  doi: 10.1371/journal.pone.0092311
– ident: e_1_2_8_30_1
  doi: 10.1093/annonc/mdp411
– ident: e_1_2_8_2_1
  doi: 10.1016/j.ejca.2010.11.033
– ident: e_1_2_8_29_1
  doi: 10.3171/2012.2.JNS111353
– ident: e_1_2_8_38_1
– ident: e_1_2_8_42_1
  doi: 10.1093/neuonc/not112
– ident: e_1_2_8_20_1
  doi: 10.1016/j.ejca.2012.07.002
– ident: e_1_2_8_3_1
  doi: 10.1007/s11060-009-0061-8
– ident: e_1_2_8_24_1
  doi: 10.1016/j.lungcan.2005.03.036
– ident: e_1_2_8_11_1
  doi: 10.1007/s11060-009-9938-9
– ident: e_1_2_8_35_1
  doi: 10.1038/bjc.2014.71
– ident: e_1_2_8_9_1
  doi: 10.1371/journal.pone.0005857
– ident: e_1_2_8_34_1
  doi: 10.1038/labinvest.2011.153
– ident: e_1_2_8_39_1
  doi: 10.1586/14737140.2013.852067
– ident: e_1_2_8_12_1
  doi: 10.5414/NP300600
– ident: e_1_2_8_6_1
  doi: 10.1111/j.1468-1331.2006.01506.x
– ident: e_1_2_8_10_1
  doi: 10.1038/nm.2072
– ident: e_1_2_8_36_1
  doi: 10.3171/2013.9.JNS13788
– ident: e_1_2_8_17_1
  doi: 10.1111/j.1365-2559.2008.03065.x
SSID ssj0005769
Score 2.3499525
Snippet Aim We aimed to characterize angiogenesis and proliferation and their correlation with clinical characteristics in a large brain metastasis (BM) series....
We aimed to characterize angiogenesis and proliferation and their correlation with clinical characteristics in a large brain metastasis (BM) series. Ki67...
Aim We aimed to characterize angiogenesis and proliferation and their correlation with clinical characteristics in a large brain metastasis ( BM ) series....
Aim We aimed to characterize angiogenesis and proliferation and their correlation with clinical characteristics in a large brain metastasis (BM) series....
AIMWe aimed to characterize angiogenesis and proliferation and their correlation with clinical characteristics in a large brain metastasis (BM)...
SourceID proquest
crossref
pubmed
wiley
istex
SourceType Aggregation Database
Index Database
Publisher
StartPage e41
SubjectTerms Adult
Aged
Aged, 80 and over
Angiogenesis
brain metastases
Brain Neoplasms - blood supply
Brain Neoplasms - mortality
Brain Neoplasms - secondary
Breast cancer
Breast Neoplasms - mortality
Breast Neoplasms - pathology
Carcinoma, Renal Cell - mortality
Carcinoma, Renal Cell - pathology
Cell Proliferation
Colorectal Neoplasms - mortality
Colorectal Neoplasms - pathology
Female
HIF-1 alpha index
Humans
Hypoxia-Inducible Factor 1, alpha Subunit - analysis
Hypoxia-Inducible Factor 1, alpha Subunit - biosynthesis
Immunohistochemistry
Kaplan-Meier Estimate
Ki-67 Antigen - analysis
ki67 proliferation index
Lung cancer
Lung Neoplasms - mortality
Lung Neoplasms - pathology
Male
Melanoma
Melanoma - mortality
Melanoma - pathology
microvascular density
Middle Aged
Neovascularization, Pathologic - mortality
Neovascularization, Pathologic - pathology
Proportional Hazards Models
Title Differential role of angiogenesis and tumour cell proliferation in brain metastases according to primary tumour type: analysis of 639 cases
URI https://api.istex.fr/ark:/67375/WNG-PXDC1ZPB-R/fulltext.pdf
https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fnan.12185
https://www.ncbi.nlm.nih.gov/pubmed/25256708
https://www.proquest.com/docview/1648870019/abstract/
https://search.proquest.com/docview/1652424399
Volume 41
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1ba9VAEB5KBfFF67XpRVYR8SUlJ9lssvapttYi9FCKxYMIy17LoTYpPTkg_gX_tDO5aUVBfEpCdjebzczst9mZbwBepFLzxEx4LPAQE4VWLEuXxFoGl3EruW3juI-n4uiMv5_lsxXYHWJhOn6I8YcbaUZrr0nBtVn8ouSVrogaoaQAcyLSI0B0-pM6CnG07HYQ8hhXMaJnFSIvnrHmjbnoFg3r1z8BzZu4tZ14Du_B56HLnb_Jxc6yMTv2229sjv_5TmtwtwekbK-ToPuw4qsHcPu433J_CN8P-hQqaAq-MHJGZHVgujqf1-dkJ-cLvHCsWV5iS4z2AdgVZQIKvpMtNq-YoTwU7NI3GrHowmMNS4tenDVZU2PxlvBiaIJ-Cr_GNjuyFHoYwhtmqd4jODt8-2H_KO4zOMSWiOdjj3DUC-Glz2RiQoFWXiSlkzJkDpGY96URLmiXJjnagiAoPVnJg8l1EQonXfYYVqu68uvAAueZL6zQpTTcWq5top1MczMxKUWORfB8-Jaq77caFjg4rKod1ghetl95LKGvL8izrcjVx-k7dTI72J98OnmjTiPYGsRA9Uq9ULiyRJNMoDiCZ-NtVEcaW135ekllcgq4QdgXwZNOfMaHpTniyyIpI3jVCsHf-6mme9P2ZOPfi27CHQRzeedRvgWrzfXSbyNgaszTVjN-AIksEe4
link.rule.ids 315,786,790,1382,27957,27958,46329,46753
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1ta9RAEB5qC-oX37XRqquI-CUll-wmWfFLba2n9kIpLR6ChM2-lKNtIr0ciH_BP-3MJjmtKIifLkd2N5vNzOwzu7PPADyLpeJRNeJhij8hUWiFMjdRqKQzCdeSa3-Oe1Kk4yP-fiqmK_BqOAvT8UMsF9xIM7y9JgWnBelftLxWNXEj5OISrKG6C-9QHfwkj0IkLbs9BBGiH5P2vEIUx7OsemE2WqOB_fonqHkRufqpZ_c6fB463UWcnGwu2mpTf_uNz_F_3-oGXOsxKdvqhOgmrNj6Flye9Lvut-H7Tp9FBa3BKaN4RNY4purjWXNMpnI2xz-GtYszbInRVgD7QsmAnO3Ei81qVlEqCnZmW4VwdG6xhia_FydO1jZY3HNeDE3QuvBLbLPjS6GHIcJhmurdgaPdN4fb47BP4hBq4p4PLSJSm6ZW2kRGlcvQ0KdRbqR0iUEwZm1epcYpE0cCzYFLKUNZzl0lVOYyI01yF1brprbrwBznic10qnJZca250pEyMhbVqIrp8FgAT4ePWfb9LgcfB4e19MMawHP_mZcl1PkJBbdlovxYvC33pzvbo0_7r8uDADYGOSh7vZ6X6FyiVSZcHMCT5W3USBpbVdtmQWUEnblB5BfAvU5-lg-LBULMLMoDeOGl4O_9LIutwl_c__eij-HK-HCyV-69Kz48gKuI7UQXYL4Bq-35wj5E_NRWj7ya_ACldBYQ
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Zb9QwEB6VVqp44T4CBQxCiJdU2cRxYngqXZZyNFpVVKwqJMvxUa1Ks1U3KyH-An-amVxQBBLiKYniK87M-LM9_gbgaSw1j8oRDwVeQqLQCmVuo1BLbxNuJDfNOe79Quwd8nezdLYGL_uzMC0_xLDgRprR2GtS8DPrf1HySldEjZCnl2CDiyQmkR4f_OSOQiAt2y2ENMRpjOhohciNZ8h6YTDaoH79-iekeRG4NiPP5Cp87tvcOpycbK_qctt8-43O8T8_6hpc6RAp22lF6DqsueoGbO53e-434fu4i6GCtuALI29EtvBMV8fzxTEZyvkSHyyrV6dYEqONAHZGoYC8a4WLzStWUiAKdupqjWB06TCHoVkvDpusXmDyhvGiL4JWhV9gmS1bClWG-IYZyncLDievP-7uhV0Ih9AQ83zoEI86IZx0iYxKn6GZF1FupfSJRSjmXF4K67WNoxSNgRcUnyznvkx15jMrbXIb1qtF5e4C85wnLjNC57LkxnBtIm1lnJajMqajYwE86f-l6tqt-hkOdqtqujWAZ81fHlLo8xNybctS9al4o6az8e7oaPpKHQSw1YuB6rR6qXBqiTaZUHEAj4fXqI_Ut7pyixWlSenEDeK-AO604jNUFqcIMLMoD-B5IwR_b6cqdorm5t6_J30Em9PxRH14W7y_D5cR2KWtd_kWrNfnK_cAwVNdPmyU5AdawxS_
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Differential+role+of+angiogenesis+and+tumour+cell+proliferation+in+brain+metastases+according+to+primary+tumour+type%3A+analysis+of+639+cases&rft.jtitle=Neuropathology+and+applied+neurobiology&rft.au=Berghoff%2C+Anna+S.&rft.au=Ilhan%E2%80%90Mutlu%2C+Ayseg%C3%BCl&rft.au=Dinhof%2C+Carina&rft.au=Magerle%2C+Manuel&rft.date=2015-02-01&rft.issn=0305-1846&rft.eissn=1365-2990&rft.volume=41&rft.issue=2&rft_id=info:doi/10.1111%2Fnan.12185&rft.externalDBID=n%2Fa&rft.externalDocID=10_1111_nan_12185
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0305-1846&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0305-1846&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0305-1846&client=summon